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The endocannabinoid system (ECS) is involved in many physiological processes and has
been suggested to play a critical role in the immune response and the central nervous
system (CNS). Therefore, ECS modulation has potential therapeutic effects on immune
dysfunctional disorders, such as sepsis and CNS injury-induced immunodeficiency
syndrome (CIDS). In sepsis, excessive release of pro- and anti-inflammatory mediators
results in multi-organ dysfunction, failure, and death. In CIDS, an acute CNS injury
dysregulates a normally well-balanced interplay between CNS and the immune system,
leading to increased patients’ susceptibility to infections. In this review, we will discuss
potential therapeutic modulation of the immune response in sepsis and CNS injury by
manipulation of the ECS representing a novel target for immunotherapy.
Keywords: endocannabinoid system, immune dysfunction, sepsis, central nervous system injury,
immunosuppression, GPR55, CNS injury-induced immunodeficiency syndrome
INTRODUCTION
The endocannabinoid system (ECS) is involved in many physiological processes including
metabolism, inflammation, pain, and neurotransmission (De Petrocellis and Di Marzo, 2009;
Pandey et al., 2009). It consists of endogenous cannabinoids (EC), cannabinoid receptors (CBR),
and EC metabolizing enzymes (De Petrocellis and Di Marzo, 2009; Pertwee et al., 2010). Two
major CBRs are identified: CBR type 1 (CB1R) and CBR type 2 (CB2R; Howlett et al., 2002). CB1R
are mainly expressed in the central nervous system (CNS) and a variety of non-neural peripheral
tissues, including the vasculature and gut (Pertwee and Ross, 2002). CB2R are primarily expressed
on immune cells but are also identified in selected CNS areas and some peripheral tissues (Klein,
2005). Recently another G protein-coupled receptor, GPR55, has garnered much attention due to
its activation by EC and its impact on the immune system (Pertwee, 2007; Yang et al., 2016a).
Increasing evidence shows that enhanced EC levels occur during systemic inflammation, such
as in sepsis or following a CNS injury. Manipulation of the ECS may have therapeutic effects in
inflammatory disorders. In this review, we will focus on modulation of CB2 and GPR55 receptors
on immune response in two inflammatory disorders, sepsis, and CNS injury. Both sepsis and CNS
injury cause the immune system to go through rather rapid and dramatic changes from pro- to anti-
inflammatory phases, which may end up costing patients their life. We suggest that the common
mechanism for modulating and ultimately controlling the response of the immune system can be
achieved through delicate interplay between the endocannabinoid, central nervous and immune
systems.
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ECS IN SEPSIS
Sepsis is defined as a life-threatening organ dysfunction caused by
a dysregulated host response to an infection (Singer et al., 2016).
An initial infection with the ensuing systemic inflammatory
response becomes amplified, resulting in excessive release of
both pro- and anti-inflammatory mediators, causing multi-organ
dysfunction, failure, and death (Kleinpell et al., 2006; Singer et al.,
2016). Recently, the ECS has emerged as a potential therapeutic
target in sepsis treatment due to its immune modulatory
functions. The effect of modulation of CB1R, CB2R, and GPR55
in sepsis-induced systemic inflammation will be described below.
CB1R
Cannabinoid receptors type 1 are mainly pre-synaptic receptors
in axon terminals and their activation causes post-synaptic
inhibition by preventing neurotransmitter release (Chevaleyre
et al., 2006; Ladak et al., 2011). Manipulating the activity of
CB1R at critical periods may play a therapeutic role in sepsis.
Studies have suggested that pre-synaptic CB1R activation on
autonomic nerves and vascular walls exacerbates the hypotension
associated with septic shock through neurogenic mechanisms
(Godlewski et al., 2004). However, studies using CB1R knockout
mice subjected to endotoxemia showed acute hypotension
indicating that other mechanisms are also responsible for
hypotension during systemic inflammatory conditions (Bátkai
et al., 2004). In a lipopolysaccharide (LPS) induced experimental
sepsis model, we demonstrated that inhibition of CB1R by its
antagonist, AM281, significantly reduced leukocyte activation
and improved intestinal microcirculation (Kianian et al., 2014)
and iris microcirculation (Kelly et al., 2010; Al-Banna et al.,
2013). However, the exact mechanisms of CB1R action in sepsis
and septic shock are not yet completely understood and further
studies are still required.
CB2R
Cannabinoid receptors type 2 are primarily expressed on immune
cells and represent an ideal target for immune modulation
(Klein, 2005). CB2R are Gi-protein coupled receptors and signal
primarily through regulating cAMP levels depending on the
duration of activation of the receptor (Rinaldi-Carmona et al.,
1998; Börner et al., 2009; Basu and Dittel, 2011). CB2R also
signal through the mitogen-activated protein kinase (MAPK)
pathway by regulating the three major kinases: the extracellular
signal-regulated protein kinases (ERK), p. 38, and c-Jun NH2-
terminal kinases (Basu and Dittel, 2011). Both of these major
signaling pathways play important roles in CB2R-mediated
immune modulating functions including effects on leukocyte
activation, migration, proliferation, apoptosis, and cytokine
production (Basu and Dittel, 2011). In general, CB2R activation
has shown an immune suppressive action, which can be exploited
for therapeutic benefit in inflammatory diseases such as sepsis.
A variety of in vitro studies have shown contradictory results
in terms of modulation of the immune response, mainly due
to the use of non-selective cannabinoids (Miller and Stella,
2008). Some studies have shown that cannabinoids enhanced
leukocyte proliferation in a dose dependent manner (Derocq
et al., 1995; Carrier et al., 2004), while other studies have
shown inhibitory effects on leukocyte proliferation through the
activation of the CB2R (Maresz et al., 2007; Basu and Dittel, 2011).
This inhibition maybe mediated by CB2R-dependent promotion
of apoptosis in dendritic cells, splenocytes, and thymocytes,
with some diminished activity when CB2R antagonists are used
(Basu and Dittel, 2011). Additional evidence also supports the
role of CB2R in the promotion of apoptosis. For example,
administration of the CB2R agonist, JWH-015, induced apoptosis
in thymocytes and diminished the proliferative potential of T
cells and B cells (Lombard et al., 2007). Administration of the
CB2R antagonist, AM630, showed a reversal of the induction of
T cell apoptosis by JWH-133 (another CB2R agonist), strongly
implicating a CB2R dependent mechanism (Singh et al., 2012).
This evidence suggests that activation of CB2R may promote
immune resolution by inducing apoptosis of immune cells,
therefore minimizing excessive damage of the pro-inflammatory
cascade that occurs early on in sepsis.
Using an experimental sepsis model, we demonstrated that
activation of CB2R by the selective CB2R agonist, HU308,
significantly reduced leukocyte adhesion in the microvasculature
(Lehmann et al., 2012). Administration of EC degradation
enzyme inhibitors, such as URB597 and JZL184, also decreased
leukocyte activation in endotoxemic animals (Sardinha et al.,
2014). However, reduced leukocyte activation by JZL184 is
still present in endotoxemic CB2R knockout mice, suggesting
that other mechanisms are also involved in the ECS-mediated
immune regulation in sepsis.
Cytokine production by immune cells plays a critical role
in the inflammatory response and can be modulated through
CB2R. Multiple pro-inflammatory cytokines, such as TNF-α,
interleukin (IL)-1β, and IL-6, are released in the early stages of
the septic cascade. However, activation of the CB2R by its agonist
HU308 reduced plasma levels of pro-inflammatory cytokines in
endotoxemic rats (Lehmann et al., 2012). Administration of the
EC, anandamide, decreased the levels of the proinflammatory
cytokines IL-12 and IL-23 in vitro in activated microglial cells
(Correa et al., 2009). In addition, T cell activation and release of
IL-2 were inhibited by administration of the CB2R agonist, JWH-
015, and this effect was eliminated by administration of the CB2R
antagonist, AM630 (Börner et al., 2009). It was also demonstrated
that activation of CB2R by HU308 enhanced the release of
IL-10, a prominent anti-inflammatory cytokine, suggesting an
immunosuppressive effect of CB2R (Klein, 2005).
GPR55
GPR55 was initially described as a novel cannabinoid receptor or
putative “CB3” receptor due to its high affinity to cannabinoid
ligands such as 19-THC, 2-AG, anandamide, and rimonabant,
independent of the presence of CB1R and CB2R (Sawzdargo
et al., 1999; Begg et al., 2005; Pertwee, 2007; Ryberg et al.,
2007). However, the limited sequence similarity between GPR55
and CBR does not support this concept (Baker et al., 2006).
Unlike the classical CB1R and CB2R signaling pathway, GPR55
is coupled to Gα12 and Gα13 proteins, signaling through ras
homolog gene family member A, Rho-associated protein kinase
and phospholipase C pathway activation. Increased intracellular
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Ca2+ is followed to activate rhoA, Rac, and cdc42, thereby
phosphorylating ERK, resulting in modulation of leukocyte
chemotaxis, proliferation, and cytokine production (Ryberg et al.,
2007; Henstridge et al., 2009).
GPR55 is widely expressed in the CNS, immune system, and
peripheral tissues and is involved in many physiological and
pathophysiological processes (Ryberg et al., 2007; Henstridge
et al., 2011). In the immune system, GPR55 is highly expressed
in the spleen and leukocytes, and its role in the modulation
of innate and adaptive immune responses suggests a potential
therapeutic effect for sepsis (Staton et al., 2008; Lin et al.,
2011; Schicho and Storr, 2012; Stancˇic´ et al., 2015). GPR55 acts
as an essential regulator in innate immunity via stimulatory
effects in neutrophils, mast cells, monocytes, and natural
killer (NK) cells (Balenga et al., 2011; Cantarella et al., 2011;
Schicho et al., 2011; Chiurchiù et al., 2015). GPR55 on NK
cells and monocytes increase pro-inflammatory cytokines, cell
cytotoxicity, and decrease monocyte-mediated endocytosis upon
activation by LPS (Chiurchiù et al., 2015). GPR55 expression
was increased in the GI tract during sepsis (Lin et al., 2011)
and GPR55 knockout mice showed least severe intestinal
inflammation in comparison to CB1R or CB2R knockout
mice in experimental colitis (Schicho and Storr, 2012). In
studies using adjuvant-induced inflammation, inflammatory
mechanical hyperalgesia by Freund’s complete adjuvant was
absent in GPR55 knockout mice with increased levels of
IL-4, IL-10, and IFN-γ (Staton et al., 2008). Importantly,
GPR55 antagonist, CID16020046, diminished inflammation in
experimental colitis by reducing the levels of pro-inflammatory
cytokines, TNF-α, IL-1β, IL-6, and impairing leukocyte activation
and migration (Stancˇic´ et al., 2015). In our laboratory, we
demonstrated that GPR55 antagonists, CID16020046, and O-
1918, reduced LPS-induced leukocyte-endothelial interactions
in experimental models of sepsis in mice (Yang et al.,
2016b).
GPR55 pharmacology with regards to ligand affinity and
activity has been controversial in the current literature due to
ligand- and concentration-specific biased signaling (Henstridge
et al., 2010; Zeng et al., 2015). GPR55 can form heteromers
with CB1R or CB2R to elicit different pathways via ligand-
and concentration-specific crosstalk (Balenga et al., 2011, 2014;
Kargl et al., 2012; Martínez-Pinilla et al., 2014). Heteromers
of CB1R and GPR55 are reported in CNS (Martínez-Pinilla
et al., 2014) and Human Embryonic Kidney cell lines (Kargl
et al., 2012). CB1R inhibits GPR55 signaling when they are
co-expressed on a cell (Kargl et al., 2012). Cross-interaction
between GPR55 and CB2R modulates partner receptor mediated
signaling. Co-expression of CB2R with GPR55 reduces GPR55
agonist-mediated activation of transcription factors, whereas
CB2 receptor-mediated signaling was inhibited by co-expression
with GPR55 (Balenga et al., 2014). GPR55-CB2R crosstalk
in neutrophils was demonstrated by the finding that GPR55
activation led to augmented neutrophil chemotaxis and reduced
CB2R-mediated tissue injury in the site of inflammation,
suggesting a possible cellular mechanism of GPR55-mediated
immune cell modulation (Balenga et al., 2011). Consequently,
further investigations on ligand-specific signaling pathways are
required to develop a specific pharmacological target for precise
and designated immune modulation.
ECS in CNS Injury
Central nervous system injury includes traumatic brain injury,
stroke, cerebral aneurysms, and spinal cord injuries. Survivors
from acute CNS injury often have complications due to
infections. The incidence of fatal infections is linked to severity
of CNS injury and the status of immune system (Klehmet
et al., 2009; Shim and Wong, 2016). Following acute CNS
injury, cell death occurs at the primary site and cytotoxins are
released, which trigger significant secondary cell death outside
the original injury area. In addition, function of the blood brain
barrier is impaired, allowing systemic inflammatory mediators
and cells to enter the normally protected CNS tissue, leading
to the pathology of a CNS injury, i.e., neuroinflammation.
The level of neuroinflammation is highly dependent on the
severity, duration, and the anatomical context of the CNS
injury. To prevent the excessive action of pro-inflammatory
cytokines after their initial beneficial effects, the immune
system releases several anti-inflammatory mediators, such as IL-
10 and IL-1 receptor antagonist and soluble tumor necrosis
factor receptors. This begins a cascade of compensatory anti-
inflammatory response. Onset of an acute CNS injury also
activates immunoinhibitory pathways, leading to a systemic
brain-mediated immunosuppression to minimize secondary
damage to healthy CNS tissue (Meisel et al., 2005; Haeusler et al.,
2012). Systemic immunosuppression is believed to be the main
reason for infections, a leading cause of death in patients with
acute CNS injury. This increased susceptibility to infections, due
to impaired immune function after an acute CNS injury, has
been termed “CNS injury-induced immunodeficiency syndrome”
(CIDS; Meisel et al., 2005).
Since the discovery of the ECS, its effects on the brain
have prompted queries into its potential physiological and
pathological roles. Local ECS is activated following CNS injury,
representing an adaptive mechanism. The primary ligands
produced in the brain are anandamide and 2-AG, which work on
both CB1R and CB2R. This may play a role in modulation of CNS
activity and regulation of the immune response after a CNS injury
(Mechoulam et al., 1995; Sugiura et al., 1995; Bisogno et al., 1999).
There are two different directions for the potential therapeutic
use of CBR: neuroprotection and immunomodulation to reduce
the CNS damage and improve the outcome.
One of the potential ways the brain protects itself is by
reducing its excitatory activity. It is proposed that activation
of presynaptic CB1R reduces the release of major excitatory
neurotransmitters, such as glutamate (Coomber et al., 2008),
which might be one of the earliest neuroprotective mechanisms
deployed by the brain to prevent excitotoxicity. This is further
supported by studies that showed blocking CB1R activity
increased the vulnerability of neurons to ischemic damage
and disrupted neuronal maintenance (Schweitzer, 2000; Hwang
et al., 2010). Additionally, complete removal of the CB1R and
associated signaling pathways causes an increase in susceptibility
to ischemic damage, excitotoxin exposure, traumatic brain injury,
and exacerbated inflammatory damage (Hillard, 2008). However,
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early inhibition of CB1R activation together with increased CB2R
activation produces beneficial effects, such as a reduction of
immune cells in cerebral vasculature, a reduction in infarct size,
and an improved motor function after transient focal ischemia
(Nagayama et al., 1999; Gilbert et al., 2007; Zhang et al., 2007;
Adhikary et al., 2011).
The mechanism that may be related to the neuroprotective
aspect of CB signaling is related to ERK in response to tissue
insults and involved in cell survival mechanisms (Scotter et al.,
2010). ERK activation is coupled to the presence of CB1R in
hippocampal regions (Marsicano et al., 2003), suggesting that
CB signaling is part of the compensatory response to CNS
injury. Neuronal maintenance aspects of CB signaling seem to
involve MAPK. Experimental support for this notion comes
from studies that showed treating the hippocampal tissue with
CB1R antagonist AM281 blocked ERK activation through MAPK
kinase and led to a compromised neuronal survival (Karanian
et al., 2005a). On the other hand, activating the CB1R and
promoting cell survival also showed the neuroprotective action
of the ECS through ERK activity (Jiang et al., 2005).
Cannabidiol, a main non-psychoactive component of
cannabis, is suggested to exhibit some of its neuroprotective
properties via inhibition of EC deactivation or even through its
effects on vanilloid and 5-HT receptors (Mishima et al., 2005;
Alvarez et al., 2008; Pazos et al., 2013). Other studies have shown
that anandamide, 2-AG, THC, and synthetic agonists of CB1R
also exhibit similar neuroprotective effects (Nagayama et al.,
1999; Panikashvili et al., 2001). Endogenous anandamide showed
neuroprotective properties in the developing brain through
CB1R activity (van der Stelt et al., 2001; Shouman et al., 2006).
Administration of 2-AG to animals with CNS injury reduced
brain edema, infarct volume, and hippocampal cell death, and
improved behavioral scores, suggesting better recovery (Shohami
et al., 1997; Panikashvili et al., 2006). The excitotoxic protective
property of ECS activation has been reversed by administration
of CB1R and CB2R antagonists, AM281 and AM630, respectively.
Other CB1R antagonists, such as SR-141716A have been shown
to reduce or completely abolish the neuroprotective properties
of EC signaling in transient global cerebral ischemia (Nagayama
et al., 1999; Marsicano et al., 2002). Despite piling evidence
suggesting the neuroprotective role of ECS, inconsistent results
and outcomes are produced. The inconsistency is due to various
factors, such as the delicacy of the physiological conditions, their
severity, the timing of the pathologic development of a CNS
injury and the pharmacological intervention. Therefore, careful
consideration needs to be given to pharmacological modulation
of ECS via CBR in terms of dosage and timing of administration,
otherwise the results may be counterproductive or even harmful.
Enhancing EC actions by targeting its degradation represents
an alternative therapeutic approach and has shown promising
results in neuroprotection. The enzyme fatty acid amide
hydrolase (FAAH) is responsible for anandamide breakdown.
Pharmacologic inhibition or genetic knockout of FAAH
promotes neuronal maintenance and function (Hwang et al.,
2010; Celorrio et al., 2016). Block of anandamide transport
with AM404 promotes CB1R signaling and enhances protection
against excitotoxicity in hippocampal slices (Karanian et al.,
2005b). Moreover, monoacylglycerol lipase (MAGL) hydrolyzes
2-AG to generate a major arachidonate precursor pool for
neuroinflammatory prostaglandins, and is suggested as a
potential drug target in neurodegenerative disease (Nomura
et al., 2011; Fernández-Suárez et al., 2014). Although there is no
direct evidence suggesting the benefit of MAGL inhibition after
CNS injury, we can speculate that the involved pathways could
be targeted to suppress proinflammatory cascades, which arise
after an acute CNS injury and contribute to exacerbated CNS
damage.
Due to the changes in the immune status after an acute
CNS injury and the onset of CIDS, CB2R expression profile
on immune cells and other non-neuronal cells suggested a
potential theoretical association between the detrimental effects
of CNS injury and CB2R activity. The immune impairment
could potentially be modulated through the activity of the CB2R,
ultimately making the patient susceptible to common infections
and worsening the outcome. In general, CB2R agonists attenuate
the inflammatory response by inhibiting production of pro-
inflammatory mediators, decreasing immune cell chemotaxis
and reducing extravasation in the vulnerable CNS (Shohami
et al., 2011; Sardinha et al., 2014). Multiple studies have
shown CB2R activation to be associated with neuroprotection
and even improved blood brain barrier function (Ramirez
et al., 2012). While many studies have established that the
CB2R activation initiates immunosuppressive mechanisms and
potentially limits neuroinflammation (Benito et al., 2008), others
have suggested that the time-course of CB2R activity may hold
the solution by avoiding the negative effects of neuroprotective
immunosuppression, while still receiving the neuroprotective
aspects of reduced neuroinflammation (Lehmann et al., 2014).
Specifically, it is suggested that the inhibition of CB2R that
is done too early could potentially increase the size of
CNS injury, as the proinflammatory cascades and neutrophil
infiltration will continue to develop. In our laboratory, we have
demonstrated inhibition of CB2R by the selective antagonist,
AM 630, significantly increased immune function as indicated
by an increased leukocyte adherence to endothelia in animals
challenged with LPS after hypoxia-ischemia (HI)-induced CNS
injury. The CB2R inhibition did not affect the magnitude of
infarct size in the injured brain (Burkovskiy et al., 2016). This
outlines both the complexity of the CNS injury pathology, as well
as the associated ECS signaling pathways, which remain to be
fully explored.
CONCLUSION
Although it has been shown that the ECS plays a vital role in the
function of the immune system, controversial results exist for its
regulatory role in sepsis, mainly due to the variety of methods
employed to activate the receptors and the lack of truly selective
ligands. In addition, in vivo studies using CB2R knockout mice
showed conflicting results, which might be attributed to the
complexity of the inflammatory models used in mimicking a
septic state. There is a growing body of evidence for a pro-
inflammatory role of GPR55 in sepsis, suggesting that selective
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GPR55 antagonists have a potential as a modulators of the
immune response, and can be designed as a therapeutic target in
sepsis.
With regards to the role of the ECS following CNS injury one
may feel that cannabinoid signaling entails the “magic bullet”
approach to many of the detrimental impairments associated
with CNS injury. However, not all aspects of cannabinoid
signaling have been fully explored and extensive pre-clinical
testing is essential to find the correct ligand (or combination of
ligands). Moreover, many of the studies have demonstrated a
close association between ECS activity and improved functional
outcome, reduced neurotoxicity, reduced infarct volume, and
other beneficial effects. While this definitely suggests a bright
future for this field, potential detrimental effects of ECS
modulation need to be studied in more detail to prevent
unwanted side effects.
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